INT224335

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 5.24
Pain Relevance 0.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) plasma membrane (KDR)
nucleus (KDR) cytoplasm (KDR)
Anatomy Link Frequency
internal 4
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 8 99.40 Very High Very High Very High
imagery 2 25.44 Quite Low
headache 4 18.40 Low Low
Pain 2 18.00 Low Low
methotrexate 3 14.88 Low Low
dexamethasone 17 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
Central nervous system 3 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
rheumatoid arthritis 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 179 100.00 Very High Very High Very High
Myeloid Leukemia 25 99.84 Very High Very High Very High
Acute Myeloid Leukemia 22 99.84 Very High Very High Very High
Inflammatory Breast Neoplasms 3 99.68 Very High Very High Very High
Apoptosis 10 99.20 Very High Very High Very High
Myelodysplastic Syndromes 29 93.36 High High
Advanced Or Metastatic Breast Cancer 23 88.44 High High
INFLAMMATION 6 87.04 High High
Appetite Loss 3 83.28 Quite High
Myelofibrosis 21 82.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Vatalanib decreased VEGF levels and VEGFR phosphorylation in AML cells, which showed FLT3 internal tandem reduplications/mutations (ITD), raising the question of the actual targeted tyrosine kinase (VEGFR or flt3).
Negative_regulation (decreased) of Phosphorylation (phosphorylation) of VEGFR in internal associated with myeloid leukemia
1) Confidence 0.35 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.72 Pain Relevance 0
Furthermore, a pilot study conducted in patients with inflammatory breast cancer demonstrated a decrease in tumour cell VEGFR2 (KDR) phosphorylation and an increase in apoptosis after a single cycle of bevacizumab therapy.
Negative_regulation (decrease) of Phosphorylation (phosphorylation) of VEGFR2 associated with inflammation, cancer and apoptosis
2) Confidence 0.29 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.71 Pain Relevance 0.05
Vatalanib decreased VEGF levels and VEGFR phosphorylation in AML cells, which showed FLT3 internal tandem reduplications/mutations (ITD), raising questions about the actual targeted tyrosine kinase (VEGFR of flt3).
Negative_regulation (decreased) of Phosphorylation (phosphorylation) of VEGFR in internal associated with acute myeloid leukemia
3) Confidence 0.25 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.83 Pain Relevance 0
PTPi I and PTPi II have both been shown to be potent inhibitors of Shp1, a phosphatase which inhibits VEGFR2 phosphorylation, and hence is a negative signaling component (36).
Negative_regulation (inhibits) of Phosphorylation (phosphorylation) of VEGFR2
4) Confidence 0.10 Published 2010 Journal Apmis Section Body Doc Link PMC2806050 Disease Relevance 0.12 Pain Relevance 0
A median decrease of 66.7% in phosphorylated VEGFR in tumor cells (p = 0.004) and a median increase of 128.9% in tumor apoptosis (p = 0.0008) were seen after bevacizumab alone.
Negative_regulation (decrease) of Phosphorylation (phosphorylated) of VEGFR associated with cancer and apoptosis
5) Confidence 0.04 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721345 Disease Relevance 0.86 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox